Related Experiment Videos
The effect of acebutolol on plasma apoproteins and HDL cholesterol subfractions
Insights
Acebutolol treatment in patients with essential hypertension significantly decreased apoprotein A-I levels and the apo A-I to apo B ratio over six months. HDL3 cholesterol also increased significantly.
Area of Science:
- Cardiology
- Clinical Pharmacology
- Biochemistry
Background:
- Essential hypertension is a common cardiovascular risk factor.
- Plasma lipoproteins, including apoproteins and HDL cholesterol subfractions, play a role in cardiovascular health.
- Understanding the impact of antihypertensive medications on these markers is crucial.
Purpose of the Study:
- To investigate the effects of oral acebutolol on plasma apoproteins A-I and B and HDL cholesterol subfractions.
- To assess changes over a 6-month treatment period in patients with essential hypertension.
Main Methods:
- 18 patients with essential hypertension received oral acebutolol for 6 months.
- Plasma levels of apoprotein A-I, apoprotein B, and HDL cholesterol subfractions (HDL2 and HDL3) were measured.
- Statistical analysis was performed to determine significant changes.
Main Results:
- A significant decrease in apoprotein A-I concentration was observed at 3 (p<0.05) and 6 months (p<0.01).
- The ratio of apoprotein A-I to apoprotein B significantly decreased during treatment.
- HDL3 cholesterol concentration increased significantly at 3 months (p<0.05), while HDL2 cholesterol showed no significant change.
Conclusions:
- Oral acebutolol therapy over 6 months favorably altered plasma lipoprotein profiles in patients with essential hypertension.
- The observed changes, particularly the decrease in apoprotein A-I and increase in HDL3, may have implications for cardiovascular risk reduction.
Abstract:
The effect on plasma apoproteins A-I and B and HDL cholesterol subfractions of acebutolol given orally over a 6-month period to 18 patients with essential hypertension was studied. The concentration of apoprotein A-I decreased during acebutolol treatment: statistical significance was reached at 3 (p less than 0.05) and 6 months (p less than 0.01). The level of apoprotein B increased slightly but not significantly. The ratio of apo A-I to apo B decreased significantly during acebutolol treatment. The concentration of total HDL cholesterol tended to be slightly but not significantly higher during therapy than before it. This increase was due to the increase of HDL3 cholesterol and this increase was significant (p less than 0.05) at 3 months. The level of HDL2 cholesterol did not change significantly during acebutolol therapy.